Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies

PLoS Computational Biology

Volumn 5, Issue 11, 2009, Pages

  Foo, Jasmine ^a   Michor, Franziska ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; CLINICAL RESEARCH; DISEASES; DRUG THERAPY; ONCOLOGY; STOCHASTIC MODELS;

ACQUIRED RESISTANCE; ANTI-CANCER THERAPIES; CANCER RESEARCH; DESIGN AND ANALYSIS; EVOLUTIONARY DYNAMICS; GENETIC ALTERATIONS; ONCOGENIC PATHWAYS; SMALL MOLECULES; STOCHASTIC MATHEMATICAL MODELS; TUMOUR CELLS;

STOCHASTIC SYSTEMS;

ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; CELL POPULATION; CLINICAL PROTOCOL; COMPUTER SIMULATION; DRUG ADMINISTRATION; DRUG PULSE THERAPY; DYNAMICS; EPIGENETICS; GENE MUTATION; PROBABILITY; STOCHASTIC MODEL; ANIMAL; BIOLOGICAL MODEL; DRUG RESISTANCE; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; MOLECULAR EVOLUTION; NEOPLASM; STATISTICS;

ANIMALS; ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; EVOLUTION, MOLECULAR; HUMANS; MODELS, GENETIC; NEOPLASM PROTEINS; NEOPLASMS; STOCHASTIC PROCESSES;

EID: 73449145303     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1000557     Document Type: Article

References (36)

1. Ross K (2004) Targeted therapies for cancer 2004. Am J Clin Path 122: 598-609.
2. Sawyers C (2004) Targeted cancer therapy. Nature 432: 294-297.
3. Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to sti-571 cancer therapy caused by bcr-abl gene mutation or amplification. Science 293: 876-880.
4. Burgess M, Sawyers C (2006) Drug-resistant phosphatidylinositol 3-kinase: Guidance for the preemptive strike. Scientific World Journal 11: 918-930.
5. Pao W, Miller V, Politi K, GJ GR, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the egfr kinase domain. PLoS Medicine 2.
6. Bentires-Alj M, Barbu V, Fillet M, et al. (2003) Nf-κβ transcription factor induces drug resistance through mdr1 expression in cancer cells. Oncogene 22: 90-97.
7. Chiang C, Sawyers C, Mcbride W (1998) Oncogene expression and cellular radiation resistance: A modulatory role for c-myc. Mol Diagn 3: 21-27.
8. Clynes M (1998) Multiple drug resistance in cancer 2: molecular, cellular and clinical aspects Kluwer Academic.
9. Dowsett M (2001) Overexpression of her-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 8: 191-195.
10. Gupta A, Bakanauskas V, Cerniglia G, et al. (2001) The ras radiation resistance pathway. Cancer Res 61: 4278-4282.
11. Townsend D, Tew K (2003) The role of glutathione-s-transferase in anticancer drug resistance. Oncogene 22: 77369-7375.
12. Hryniuk W (2001) Dosage parameters in chemotherapy of breast cancer. Breast Disease 14: 21-30.
13. Lake D, Hudis C (2004) High-dose chemotherapy in breast cancer. Drugs 64: 1851-1860.
14. Hahnfeldt P, Folkman J, Hlatky L (2003) Minimizing long-term tumor burden: The logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol 220: 545-554.
15. Norton L, Simon R (1977) Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61: 1307-1317.
16. Norton L, Simon R (1986) The norton-simon hypothesis revisited. Cancer Treat Rep 70: 163-169.
17. Citron M, et al. (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial c9741/cancer and leukemia group b trial 9741. J Clin Oncol 21: 1431-1439.
18. Dibrov B, Zhabotinsky A, Neyfakh Y, Orlova M, Churikova L (1983) Optimal scheduling for cell synchronization by cycle-phase-specific blockers. Math Biosci 66: 167-185.
19. Agur Z (1986) The effect of drug schedule on responsiveness to chemotherapy. Ann Acad New York Sci 504: 274-277.
20. Panetta J (1996) A mathematical model of periodically pulsed chemotherapy: Tumor recurrence and metastasis in a competitive environment. Bull Math Biol 58: 425-447.
21. Costa M, Boldrini J, Bassanezi R (1995) Drug kinetics and drug resistance in optimal chemotherapy. Math Biosci 125: 191-209.
22. Gardner S, Fernandes M (2003) New tools for cancer chemotherapy: computational assistance for tailoring treatments. Mol Cancer Therapeutics 2: 1079-D1084.
23. Swan G (1990) Role of optimal control in chemotherapy. Math Biosci 101: 237-284.
24. Martin R, Teo K (1994) Optimal control of drug administration in cancer chemotherapy World Scientific Publishin.
25. Coldman A, Goldie J (1986) A stochastic model for the origin and treatment of tumors containing drug-resistant cells. Bull Math Biol 48: 279-292.
26. Coldman A, Murray J (2000) Optimal control for a stochastic model of cancer chemotherapy. Math Biosciences 168: 187-200.
27. Day R (1986) Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy. Cancer Research 46: 3876-3885.
28. Iwasa Y, Michor F, Nowak M (2003) Evolutionary dynamics of escape from biomedical intervention. Proc Roy Soc Lond B 270: 2572-2578.
29. Komarova N, Wodarz D (2005) Drug resistance in cancer: Principles of emergence and prevention. PNAS 102: 9714-9719.
30. Komarova N (2006) Stochastic modeling of drug resistance in cancer. J Theor Biol 239: 351-366.
31. Iwasa Y, Nowak M, Michor F (2006) Evolution of resistance during clonal expansion. Genetics 172: 2557-2566.
32. Haeno H, Y YI, Michor F (2007) The evolution of two mutations during clonal expansion. Genetics 177: 2209-2221.
33. Athreya K, Ney P (2004) Branching processes Dover Press.
34. Hidalgo M, Siu L, Nemunaitis J, et al. (2001) Phase I and pharmacologic study of osi-774, and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Journal of Clinical Oncology 19: 3267-3279.
35. Soulieres D, Senzer N, Vokes E, et al. (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. Journal of Clinical Oncology 11: 77-85.
36. Milton D, Azzoli C, Heelan R, et al. (2006) A phase I/II study of weekly highdose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 107: 1034-1041.